Benzinga | Jun 4, 2021 06:09AM EDT

HC Wainwright & Co. Initiates Coverage On C4 Therapeutics with Buy Rating, Announces Price Target of $63

HC Wainwright & Co. analyst Andrew Fein initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Buy rating and announces Price Target of $63.